Press coverage about Odonate Therapeutics (NASDAQ:ODT) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Odonate Therapeutics earned a coverage optimism score of 0.02 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.8263534563928 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Odonate Therapeutics stock traded up $0.18 on Friday, reaching $20.40. 9,396 shares of the stock were exchanged, compared to its average volume of 39,018. The firm has a market cap of $548.32 million and a price-to-earnings ratio of -8.83. Odonate Therapeutics has a twelve month low of $15.15 and a twelve month high of $32.00.

Odonate Therapeutics (NASDAQ:ODT) last released its earnings results on Monday, July 30th. The company reported ($0.79) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.03. analysts forecast that Odonate Therapeutics will post -3.42 earnings per share for the current year.

ODT has been the subject of a number of recent research reports. ValuEngine upgraded shares of Odonate Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of Odonate Therapeutics from a “hold” rating to a “buy” rating and set a $26.00 price objective for the company in a report on Thursday, May 10th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $31.00.

In other news, CEO Kevin C. Tang bought 22,810 shares of the business’s stock in a transaction on Wednesday, August 15th. The stock was purchased at an average price of $18.93 per share, with a total value of $431,793.30. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kevin C. Tang bought 49,685 shares of the business’s stock in a transaction on Monday, August 20th. The shares were purchased at an average cost of $19.49 per share, with a total value of $968,360.65. The disclosure for this purchase can be found here. 49.00% of the stock is owned by insiders.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.

Featured Article: Dividend Stocks – Are They Right For You?

Insider Buying and Selling by Quarter for Odonate Therapeutics (NASDAQ:ODT)

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with's FREE daily email newsletter.